INHIBRX BIOSCIENCES INC (INBX) Earnings History & Surprises

NASDAQ:INBX • US45720N1037

73.5 USD
+1.87 (+2.61%)
At close: Mar 11, 2026
73.5 USD
0 (0%)
After Hours: 3/11/2026, 8:04:10 PM

Past quarterly earnings results for INHIBRX BIOSCIENCES INC (INBX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).

Earnings Snapshot

Next Earnings Date

Upcoming
Release DateMar 23, 2026
PeriodQ4 / 2025
EPS Estimate-$2.12
Revenue Estimate

Last Reported

Most Recent
Release DateNov 14, 2025
PeriodQ3 / 2025
EPS Reported-$2.28
EPS Surprise -30.11%
Revenue Surprise %

Beat Rate

Last 8 Quarters
25%
EPS and Revenuebeats vs estimates

Quarterly Earnings Results

EPS & Revenue History (USD)

Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.

QuarterEPSEPS EstEPS SurpriseEPS Q2QRevenueRevenue EstRevenue SurpriseRevenue Q2Q
Q3 2025 -2.28 -1.75 -30.11% 19.72% - -
Q2 2025 -1.85 -2.82 34.31% -101.47% 1.3M - 1,200.00%
Q1 2025 -2.80 -2.90 3.29% -94.44% - -
Q4 2024 -3.09 -2.94 -4.97% -78.61% 100K - -93.88%
Q3 2024 -2.84 -3.45 17.60% -158.18% - -
Q2 2024 125.48 -3.67 3,517.21% 11,718.52% 100K - 233.33%
Q1 2024 -1.44 -1.06 -35.75% -28.57% 51K -100.00% -100.00%
Q4 2023 -1.73 -1.06 -63.61% -82.11% 1.634M 51K 3,103.92% 505.19%
Q3 2023 -1.10 -1.03 -6.78% -22.22% 120K - -100.00%
Q2 2023 -1.08 -1.05 -2.50% -11.34% 30K - -95.77%
Q1 2023 -1.12 -0.86 -30.10% -40.00% 17K 153K -88.89% -98.17%
Q4 2022 -0.95 -0.80 -18.19% -72.73% 270K 809.88K -66.66% -90.56%
Q3 2022 -0.90 -0.96 6.23% -66.67% 280K 645.997K -56.66% -88.93%
Q2 2022 -0.97 -0.79 -22.16% -76.36% 710K 1.09M -34.86% -25.26%
Q1 2022 -0.80 -0.61 -30.87% -56.86% 930K 1.124M -17.26% 4.49%
Q4 2021 -0.55 -0.58 5.79% -17.02% 2.86M 1.742M 64.18% 2.88%
Q3 2021 -0.54 -0.58 6.85% 29.87% 2.53M 1.02M 148.04% -57.12%
Q2 2021 -0.55 -0.57 2.93% - 950K 841.5K 12.89% -71.56%
Q1 2021 -0.51 -0.60 15.04% - 890K 943.5K -5.67% 2.30%
Q4 2020 -0.47 -0.55 14.98% - 2.78M 1.014M 174.16% -
Q3 2020 -0.77 -0.62 -25.05% - 5.9M 1.02M 478.43% -
Q2 2020 - - 3.34M - -
Q1 2020 - - 870K - -

Notes

  • EPS and Revenue values are non-GAAP when available, otherwise GAAP.
  • Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
  • Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
  • Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.

Earnings Q2Q Performance Trends

EPS Historical Q2Q growth and Acceleration

INBX EPS Q2Q GrowthINBX EPS Q2Q GrowthEPS Q2Q Growth Q3/21 Q1/22 Q3/22 Q1/23 Q3/23 Q1/24 Q3/24 Q1/25 Q3/25 Q1/26 Q3/26 Q1/27 Q3/27 Q1/28 Q3/28 0 2K 4K 6K 8K 10K

Revenue Historical Q2Q growth and Acceleration

INBX Revenue Q2Q GrowthINBX Revenue Q2Q GrowthRevenue Q2Q Growth Q1/21 Q2/21 Q3/21 Q4/21 Q1/22 Q2/22 Q3/22 Q4/22 Q1/23 Q2/23 Q3/23 Q4/23 Q1/24 Q2/24 Q4/24 Q2/25 Q4/25 Q2/26 0 200 400 600 800 1K

Surprise distribution (Last 4 Quarters)

EPS beat statistics

EPS beat (4)
2
Average EPS beat (4)
0.63%
Max EPS beat (4)
34.31%
Min EPS beat (4)
-30.11%

Revenue beat statistics

Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A

Analysis

In the last 4 quarters, INBX has beaten EPS estimates in 2 out of 4 releases
In the last 4 quarters, INBX has beaten the EPS estimates by 0.6% on average.
→ Find peers who consistently beat earnings by at least 10% in the last 4 quarters

INHIBRX BIOSCIENCES INC / INBX Earnings FAQ

What is the most recent earnings date for INBX stock?

INHIBRX BIOSCIENCES INC (INBX) last reported earnings on 11/14/2025.


Did INBX stock beat earnings estimates in the most recent quarter?

INHIBRX BIOSCIENCES INC (INBX) missed EPS estimates and missed revenue estimates in the most recent quarter.


What percentage of the time does INBX stock beat earnings estimates?

In the last 4 quarters, INHIBRX BIOSCIENCES INC (INBX) has beaten EPS estimates in 2 out of 4 releases.